Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
Mini
5
Ṁ152Jan 1
36%
chance
1D
1W
1M
ALL
The reporting must be within 2024, so if the reporting happens in January 2025 regarding Q4 2024, then this still resolves NO.
Get Ṁ1,000 play money
Related questions
Related questions
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will Kim Jong Un start taking Ozempic (or any GLP-1) by the end of 2025?
20% chance
More than 10% of US citizens will be on prescription drugs for weight loss by 2031
61% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
83% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
65% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
14% chance